{"id":"placebo-of-pr-tablet","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3314608","moleculeType":"Small molecule","molecularWeight":"691.87"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inert formulations used as control comparators in clinical trials to distinguish the true pharmacological effects of an active drug from placebo response (psychological and contextual effects). In a Phase 3 trial, the placebo PR tablet serves as the comparator arm to evaluate the efficacy and safety of the active investigational drug.","oneSentence":"A placebo tablet contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:13.280Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT04806737","phase":"PHASE1, PHASE2","title":"Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-04-16","conditions":"Celiac Disease","enrollment":15},{"nctId":"NCT01958021","phase":"PHASE3","title":"Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-17","conditions":"Advanced, Metastatic Breast Cancer","enrollment":668},{"nctId":"NCT03581773","phase":"PHASE2","title":"Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2017-12-20","conditions":"Mucositis, Stomatitis","enrollment":100},{"nctId":"NCT03263026","phase":"PHASE3","title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2018-03-20","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":256},{"nctId":"NCT03785756","phase":"PHASE3","title":"Efficacy of 300 mg Ibuprofen Prolonged-Release Tablets for the Treatment of Pain After Surgical Removal of Impacted Third Molars","status":"COMPLETED","sponsor":"Reckitt Benckiser Healthcare (UK) Limited","startDate":"2019-04-29","conditions":"Pain","enrollment":280},{"nctId":"NCT02278120","phase":"PHASE3","title":"Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-11-20","conditions":"Advanced Metastatic Breast Cancer","enrollment":672},{"nctId":"NCT06267794","phase":"PHASE2","title":"Prolonged Release Pirfenidone Versus Placebo in Compensated Cirrhosis.","status":"COMPLETED","sponsor":"Jorge L Poo","startDate":"2015-06-26","conditions":"Liver Fibrosis, Cirrhosis, Liver, Chronic Liver Disease","enrollment":180},{"nctId":"NCT03078751","phase":"PHASE2","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-20","conditions":"Breast Cancer","enrollment":54},{"nctId":"NCT01964378","phase":"PHASE3","title":"CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer","status":"TERMINATED","sponsor":"Tris Pharma, Inc.","startDate":"2013-10-29","conditions":"Pain, Neoplasms, Chronic Pain","enrollment":200},{"nctId":"NCT04893993","phase":"PHASE4","title":"PBC Induced Fatigue Treated With Thiamine","status":"UNKNOWN","sponsor":"Henning Grønbæk","startDate":"2021-05-12","conditions":"Primary Biliary Cirrhosis","enrollment":36},{"nctId":"NCT00463385","phase":"PHASE2","title":"A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia","status":"COMPLETED","sponsor":"Celgene","startDate":"2007-04-01","conditions":"Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis","enrollment":88},{"nctId":"NCT00472303","phase":"PHASE3","title":"A Study to Evaluate Tapentadol (CG5503) in the Treatment of Chronic Tumor-Related Pain Compared With Placebo and Morphine","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2007-07","conditions":"Tumor, Pain","enrollment":622},{"nctId":"NCT03951402","phase":"PHASE1","title":"Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2003-03","conditions":"Prolonged QTc Interval, Pharmacokinetic","enrollment":48},{"nctId":"NCT03776110","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT9906 Prolonged Release Tablets After Dose Escalation in Healthy Subjects","status":"COMPLETED","sponsor":"Grünenthal GmbH","startDate":"2004-09-15","conditions":"Pharmacokinetics","enrollment":48},{"nctId":"NCT01197261","phase":"PHASE2","title":"OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-09","conditions":"Interstitial Cystitis, Painful Bladder Syndrome, Pain","enrollment":120},{"nctId":"NCT01112644","phase":"PHASE3","title":"Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2010-04","conditions":"Moderate to Severe Idiopathic RLS With Daytime Symptoms","enrollment":205},{"nctId":"NCT03687268","phase":"PHASE3","title":"Naloxone HCl PR Tablets in Patients With Opioid Induced Constipation","status":"UNKNOWN","sponsor":"Develco Pharma Schweiz AG","startDate":"2017-07-31","conditions":"Opioid-Induced Constipation","enrollment":1500},{"nctId":"NCT01154166","phase":"PHASE3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-15","conditions":"Parkinson Disease","enrollment":347},{"nctId":"NCT03081234","phase":"PHASE3","title":"Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2018-03-31","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT02078973","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2014-03-01","conditions":"Nephropathy","enrollment":15},{"nctId":"NCT02527863","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2015-02","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":18},{"nctId":"NCT01597297","phase":"PHASE2","title":"Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2012-08","conditions":"Multiple Sclerosis","enrollment":132},{"nctId":"NCT02789592","phase":"PHASE2","title":"Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-07","conditions":"REM Sleep Behavior Disorder, Parkinson Disease","enrollment":30},{"nctId":"NCT02392676","phase":"PHASE3","title":"Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2016-07","conditions":"Platinum Sensitive Relapsed Ovarian Cancer","enrollment":""},{"nctId":"NCT01208701","phase":"PHASE2","title":"The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy","status":"COMPLETED","sponsor":"Erling Bjerregaard Pedersen","startDate":"2010-05","conditions":"Nephropathy, Cardiovascular Diseases, Diabetes Mellitus","enrollment":25},{"nctId":"NCT00110994","phase":"PHASE2","title":"Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-04","conditions":"Cancer, Melanoma","enrollment":101},{"nctId":"NCT01377025","phase":"PHASE2","title":"A Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma","status":"UNKNOWN","sponsor":"Prof. Dr. med. Max. E. Scheulen","startDate":"2011-06","conditions":"Uveal Melanoma","enrollment":200},{"nctId":"NCT00111007","phase":"PHASE3","title":"A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-05","conditions":"Melanoma","enrollment":270},{"nctId":"NCT01638663","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2012-05","conditions":"Cardiovascular Diseases, Nephropathy","enrollment":20},{"nctId":"NCT00882908","phase":"PHASE2","title":"A Study of TMC435 in Combination With Pegylated Interferon Alp\\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-06","conditions":"Hepatitis C","enrollment":386},{"nctId":"NCT00980330","phase":"PHASE2","title":"A Safety and Effectiveness Study of TMC435 in Chronic, Genotype 1, Hepatitis C Patients Who Failed to Previous Standard Treatment","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2009-10","conditions":"Hepatitis C","enrollment":463},{"nctId":"NCT00561353","phase":"PHASE2","title":"A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-01","conditions":"Hepatitis C, Chronic","enrollment":121},{"nctId":"NCT00307684","phase":"PHASE3","title":"Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2006-01","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":155},{"nctId":"NCT01439100","phase":"PHASE3","title":"A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain","status":"COMPLETED","sponsor":"Mundipharma Research GmbH & Co KG","startDate":"2011-10","conditions":"Parkinson's Disease With Severe Pain","enrollment":172},{"nctId":"NCT01292239","phase":"PHASE3","title":"A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2011-02","conditions":"Hepatitis C, Chronic","enrollment":183},{"nctId":"NCT00923156","phase":"PHASE2","title":"Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Heart Failure","enrollment":123},{"nctId":"NCT01390662","phase":"PHASE4","title":"Can Vitamin D3 Supplementation Affect Treatment Outcomes in Patients With Depression","status":"UNKNOWN","sponsor":"Region Syddanmark","startDate":"2011-03","conditions":"Depression","enrollment":150},{"nctId":"NCT01214746","phase":"PHASE2","title":"The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2010-05","conditions":"Cardiovascular Diseases, Nephropathy","enrollment":26},{"nctId":"NCT00745069","phase":"PHASE2","title":"Efficacy and Safety of Tapentadol Extended Release Tablets in the Treatment of Moderate to Severe Pain in Subjects With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2004-07","conditions":"Osteoarthitis, Chronic Pain, Knee Pain","enrollment":670}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo of PR tablet","genericName":"Placebo of PR tablet","companyName":"Reckitt Benckiser Healthcare (UK) Limited","companyId":"reckitt-benckiser-healthcare-uk-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}